Dr. Reddy’s to Increase R&D Spending

Pharmaceutical major Dr. Reddy’s Laboratories (DRL) aims to increase the R&D spending on its three major research programmes, including the reverse cholesterol transport (RCT) area, in a bid to come out with pathbreaking molecules in the next 7–10 years.
Business Standard